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ELEMENT PLAN – HUMAN HEALTH COUNTERMEASURES 
 
PART I: ELEMENT OVERVIEW 
1.0 Introduction 
NASA’s Human Research Program (HRP) is an applied research and technology program within 
the Human Exploration and Operations Mission Directorate (HEOMD) that addresses human 
health and performance risk mitigation strategies in support of exploration missions. The HRP 
research and technology development is focused on the highest priority risks to crew health 
and safety with the goal of ensuring mission success and maintaining long-term crew health.  
Crew health and performance standards, defined by the NASA Chief Health and Medical Officer 
(CHMO), set the acceptable risk level for exploration missions. The HRP conducts research to 
inform these standards as well as provide deliverables, such as countermeasures, that ensure 
standards can be met to maximize human performance and mission success. 
The Human Health Countermeasures (HHC) Element was formed as part of the HRP to develop 
a scientifically-based, integrated approach to understanding and mitigating the health risks 
associated with human spaceflight. These health risks have been organized into four research 
portfolios that group similar or related risks. A fifth portfolio exists for managing technology 
developments and infrastructure projects. The HHC Element portfolios consist of: 
• Vision and Cardiovascular 
• Exercise and Performance 
• Multisystem 
• Bone 
• Technology and Infrastructure 
The HHC identifies gaps associated with the health risks and plans human physiology research 
that will result in knowledge required to more fully understand risks and will result in validated 
countermeasures to mitigate risks.  
The Flight Analogs Project (FAP) will be moving out of the HHC beginning in FY13. The Bed Rest 
Standard Measures funding and oversight will remain with the HHC in the Technology and 
Infrastructure Portfolio. For FY12, the entire FAP will remain part of HHC and be managed as a 
part of the Technology and Infrastructure Portfolio. The current FAP project plan will remain in 
effect through FY12. 
A separate project plan will be developed for the Digital Astronaut Project (DAP). Through 
computational simulation, the DAP provides human modeling services to the HHC research 
portfolios to assist in closing the HRP risks and gaps.  
1.1 Purpose 
The purpose of this Element Plan is to establish HHC objectives, management approach, roles 
and responsibilities, organization, and the relationships that are necessary to achieve the 
Element goals within the scope of the HRP Program Plan (HRP-47051). This Element Plan 
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complies with the requirements of NPR 7120.8 – NASA Research and Technology Program and 
Project Management. Changes to this Plan will be controlled by the HRP Control Board (HRPCB). 
1.2 Objectives 
The goal of the HRP is to provide human health and performance countermeasures, knowledge, 
technologies, and tools to enable safe, reliable, and productive human space exploration.  
The research that HHC performs facilitates the HRP in either eliminating human health and 
performance risks and knowledge gaps, or confirming and guiding plans for the resolution of 
the risks and/or gaps.  
The HHC objectives are a direct flow-down from program requirements in the HRP Program 
Requirements Document (PRD) (HRP-47052, Rev. E). These objectives may be grouped under 
three goals:  
• Develop countermeasures and technologies to mitigate validated physiologic risks 
• Develop technologies to reduce human system resource requirements 
• Maintain Agency core competencies 
Goal 1: Develop capabilities, necessary countermeasures, and technologies, focusing on 
mitigating the highest risks associated with human spaceflight for the various exploration 
missions. 
Trace: HRP PP (HRP-47051) Section 1.2.1 
Objective 2.1: Quantify the human health and performance risks associated with human 
spaceflight for exploration missions.  
Trace: HRP PRD (HRP-47052) Section 5.1 
Objective 2.2: Develop countermeasures and technologies to prevent or mitigate adverse 
outcomes of human health and performance risks.  
Trace: HRP PRD (HRP-47052) Section 5.2 
Objective 2.3: Develop countermeasures and technologies to monitor and treat adverse 
outcomes of human health and performance risks.  
Trace: HRP PRD (HRP-47052) Section 5.3 
Goal 2: Develop technologies that serve to reduce medical risks, to reduce human systems 
resource requirements, and to ensure effective human system integration. 
Trace: HRP PP (HRP-47051) Section1. 2.1 
Objective 3.1: Develop technologies to reduce human systems resource requirements 
(mass, volume, power, data, etc.) 
Trace: HRP PRD (HRP-47052) Section 6.4 
Goal 3: Maintain NASA’s core competency in space life sciences. 
Trace: HRP PP (HRP-47051) Section 1.2.1 
Objective 4.1: Ensure processes and products comply with the NASA policy directives and 
NASA procedural requirements.  
Trace: HRP PRD (HRP-47052) Section 6.3 
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Successful achievement of Element objectives will be determined through annual review by the 
HHC Standing Review Panels (SRPs) based upon: definition and clarity of requirements 
identified, implementation plan and review processes, maturity of deliverables, validation and 
operational availability of deliverables for implementation, transition of end-item program 
Element deliverables to customer programs, mitigation of physiologic risks, retirement of 
risks/gaps, and potential generation of new risks/gaps. 
Specific deliverables resulting from these Element objectives will enhance the understanding of 
physiologic needs, improve availability of effective countermeasures for selection, and make 
available innovative technologies for diagnosis and intervention in space. 
1.3 Mission Description 
The HRP was formed to manage research investments focused on investigating and mitigating 
the highest risks to astronaut health and performance in support of exploration missions (HRP-
47051). The HRP provides deliverables that specifically support NASA’s exploration architecture. 
The HHC Element maintains an active engagement with the organizations developing concepts 
for mission architectures. The HHC studies the design reference missions (DRMs) that provide a 
framework to identify key capabilities and important guiding drivers and assumptions, thus 
enabling the HHC to focus research questions on topics highly relevant to NASA’s future 
activities. 
1.4 Customer and Stakeholder Definition and Advocacy  
The HHC supports HEOMD efforts in executing exploration missions.  
The HHC generates outcomes and products for the following primary customers as part of the 
HRP. These are: (1) Human Exploration and Operations Mission Directorate (HEOMD), (2) Office 
of Chief Health and Medical Officer (OCHMO) and its assigned Health and Medical Technical 
Authority (HMTA) and (3) exploration and vehicle development projects. 
The major stakeholders of HHC products are the HRP, Chief Health and Medical Officer, flight 
surgeons, the ISS Program, the Astronaut Office, Flight Control Teams, and spacecraft 
development project offices. Other stakeholders include: the NASA Science Mission 
Directorate, the JSC Space Life Sciences Directorate (SLSD), the Human Adaptation & 
Countermeasures Division (HACD), the Habitability & Environment Factors Division (HEFD), the 
Space Medicine Division (SMD), the National Space Biomedical Research Institute (NSBRI), and 
the external research and technology (R&T) community.  
1.5 Element Authority  
The HRP is divided into 6 major Elements identified in Figure 1-1. An Element consists of the 
aggregation of related portfolios and research tasks focused toward developing products that 
reduce risks to the crew. The HHC is divided into four research portfolios as identified in Section 
1.6.1. Each portfolio is characterized as an integrated set of tasks designed to deliver a product 
or set of products to a designated customer on a specified date.  
The HRP Program Plan delegates management of the HHC to the Johnson Space Center (JSC). 
The HHC management team organizationally resides within the SLSD at the JSC. Overall 
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management of the HHC is assigned to an Element Manager (EM) within the HACD of the SLSD 
at the JSC. 
 
 
Figure 1-1: Human Research Program structure. 
As described in the HRP Program Plan, overall responsibility for the HRP lies with the Program 
Manager and Deputy Program Manager. The HRP has funding authority for the HHC, approves 
the Element Management Plan, and has final approval of delivered products.  
The HRP Program Plan authorizes the Element Manager (EM) and Element Scientist (ES) to 
execute the Element according to the procedures and policies of the Agency, HEOMD, HRP, JSC, 
and the respective Field Centers. The HHC develops and maintains inter-Center agreements, 
coordinates all R&T tasks, maintains performance metrics and schedules, and supports the HRP 
in the development of future strategic direction. The EM and ES have full authority to make and 
implement decisions that meet scientific objectives of the Element, are within assigned 
resources, do not have a direct impact on control milestones, nor impact resources, schedule, 
or objectives of another Element. If any of these criteria cannot be met, then the decision must 
be elevated to the next higher level of authority. 
1.6 Management  
To ensure the HRP deliverables can be ready in time to support NASA’s exploration mission 
needs, the HRP applies project management principles to the management of all HRP activities. 
The EM is responsible for overall performance of the Element as well as performing the tasks 
necessary to enable research tasks within the Element. The ES is responsible for the scientific 
content and direction within the Element. The ES will provide recommendations to the HRP 
regarding selection of NASA Research Announcement (NRA) awards and performance of 
research studies that meet the HRP requirements and address Agency needs, goals, and 
objectives. Integration within the HHC is the responsibility of the EM and ES. The EM and ES 
work as a team to manage all of the various activities in an effective manner. The ES provides 
recommendations to the EM regarding selection and performance of research studies that 
meet the HRP requirements and address Agency needs, goals and objectives.  
Integration across the Elements is the responsibility of the Program Manager and Chief 
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Scientist, and they are supported by Element coordination. Integration within an Element is the 
responsibility of the EM and ES. For example, the HHC’s EM and ES integrate research and 
products across various HHC portfolios to deliver an integrated set of deliverables focused on 
risk management and countermeasure development. 
1.6.1 Structure 
The Element management structure provides a single focal point to develop a scientifically-
based integrated approach to understanding, projecting, and mitigating the crew health risks 
associated with spaceflight. This provides an environment wherein research efforts can be 
properly planned, conducted, and maintained. Oversight of the HHC is the responsibility of the 
HRP. The HHC, as a multi-portfolio Element, identifies issues that span across portfolios and 
divisions to enhance shared capabilities and prevent duplication of efforts. The organizational 
structure of the HHC can be found in Figure 1-2. 
 
Figure 1-2: HHC Program Element Structure. 
Acronyms used on chart: 
rVIIP  research Visual Impairment and Intracranial Pressure 
NSBRI  National Science Biomedical Research Institute 
OxDam  Oxidative Stress and Damage 
EVA  Extravehicular Activity 
DCS  Decompression Sickness 
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Osteo  Osteoperosis 
IVD  Intervertebral Disc Damage 
Renal  Renal Stone 
1.6.2 Roles and Responsibilities 
The HRP management team provides oversight of the execution of the Element, reviews the 
Element with the EM/ES team at least once each quarter, reviews interim deliverables, and 
provides guidance about the deliverables, resolves issues between the EM and the ES, resolves 
intra-HRP Element conflicts, overlaps and gaps, identifies opportunities for intra-HRP 
collaborations, cost or risk mitigations, and other strategies to improve performance and HRP 
success.  
The HHC management team provides oversight of the execution of the portfolios within HHC; 
reviews the portfolios with the Portfolio Manager and Lead Scientists team at least once each 
quarter; reviews interim deliverables and provides guidance about the deliverables; resolves 
issues between the Portfolio Manager and Lead Scientists; resolves intra-HHC conflicts, 
overlaps and gaps; and identifies opportunities for intra-HHC collaborations, cost or risk 
mitigations, and other strategies to improve performance and HHC success.  
The Portfolio management teams provide oversight to tasks assigned to their portfolio.  
The roles and responsibilities for the HHC management team and key Program Element 
organizational interfaces are summarized below. 
1.6.2.1 HHC Element Management Team [top blue box on Figure 1-2] 
The HHC structure relies on a management team consisting of the EM, Deputy EM, ES and 
Deputy ES. The HHC management team ensures all technical requirements are met as well as all 
JSC Division, Directorate, and Center management requirements. The HHC uses common 
approaches, tools, and procedures for managing the Program Element. 
1.6.2.1.1 HHC Element Manager (EM) 
The EM is responsible for the day-to-day management of the Program Element, including 
budget management, reporting, schedules, and logistics.  
The EM reports to the HRP Program Manager and ensures that Program Element decisions are 
made in a timely manner with the consensus of the entire management team. The EM follows 
established principles, best practices and guidelines in Project Management, and is authorized 
to work with the ES to:  
• Form the Element team  
• Plan the Element  
• Establish subordinate Element structure and work with line management to provide 
managers and personnel 
• Allocate requirements and resources to projects/portfolios 
• Integrate cost and schedule across subordinate organization 
• Develop and maintain a comprehensive schedule and a cost estimate  
• Follow established change management processes  
• Identify, assess, track and mitigate risks  
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• Implement/execute the Element per approved Element Plan  
• Serve as the Element’s official interface with the HRP  
• Report Element progress and status to the HRP, HACD, and branch management  
• Develop Customer-Supplier Agreements (CSAs) 
The Deputy EM supports the EM and represents the Element in the event the EM is not 
available. The EM relies heavily on the expertise of the rest of the Element management team, 
consisting of the ES and Deputy ES. 
1.6.2.1.2 HHC Element Scientist (ES) 
The ES reports to the HRP Chief Scientist. The ES is a key member of the Element leadership and 
management team, and is responsible for the technical content and direction of the HHC. The 
ES ensures that decisions of the Element Management team and staff are scientifically well 
informed. The ES is responsible for ensuring that the scientific requirements are met with 
results reported in a timely manner. If sufficient budget is not available to implement all 
requirements, the ES will coordinate with the HHC management team to prioritize the research. 
The ES will follow the established principles, best practices and guidelines in scientific research, 
and is authorized to work with the EM to:  
• Provide the strategic direction for Element and support Element planning  
• Develop a comprehensive research plan and schedule of planned science to meet 
exploration milestones  
• Allocate requirements and research plans to subordinate portfolios 
• Integrate technical plans and progress across subordinate portfolios 
• Follow established scientific research processes  
• Facilitate clear and accurate communications on matters related to the science 
objectives of the Element, and lead analysis of scientific and developmental 
requirements, priorities, impacts and tradeoffs  
• Provide technical direction to the HHC Lead scientists  
• Facilitate technical discussions with the NSBRI, external principal investigators, and Lead 
scientists to address the HHC actions, objectives, and deliverables  
• Serve as a liaison to concurrent Element teams 
• Act as point of contact for technical information about the HHC  
• Coordinate HHC inputs to and selection recommendations for the annual NRA 
• Report Element science progress and status to the HACD and branch management as 
appropriate 
There may be more than one Deputy ES assigned to this Element; the Deputy ES supports the 
ES, and represents the Element in the event the ES is not available. 
1.6.2.1.3 HHC Portfolio Managers (PM) [2nd
The Portfolio Managers (PM) report to the HHC Element Manager and ensures that portfolio 
decisions are made in a timely manner with the consensus of the relevant Lead Scientist(s). The 
PM follows established principles, best practices, and guidelines in Project Management, and is 
authorized to work with the Lead Scientists to:  
 level blue boxes on Figure 1-2] 
• Manage each risk or group of risks as a project 
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• Provide project management support to the Element (e.g., integrated master schedule 
[IMS] updates, technical cost and schedule reviews [TCSRs], planning, programming, 
budgeting, and execution [PPBE] packages) 
• With the HHC budget analyst team, actively manage grants to reduce cost carryout 
• With the HHC budget analyst team, control portfolio budget (identification of threats, 
liens and opportunities) 
• Integrate NSBRI tasks into portfolio for reporting (IMS, Integrated Research Plan [IRP], 
deliverables) 
1.6.2.1.4 HHC Lead Scientists (LS) [Green boxes on Figure 1-2] 
The Lead Scientists (LSs) report to the HHC ES. There are a number of LSs in each portfolio and 
each LS is a key members of the portfolio management team, and is responsible for the 
technical content and direction of research plans associated with their assigned risks. The LSs 
ensure that the objectives, requirements, and assumptions for the assigned risks and 
mitigations are clearly identified, communicated, documented, and controlled, and that the 
decisions of the Portfolio Manager are scientifically well informed. If sufficient budget is not 
available to implement all requirements, the LSs will coordinate with the portfolio and HHC 
management team to prioritize the research. The LSs will follow the established principles, best 
practices, and guidelines in scientific research, and are authorized to work with the Portfolio 
Manager to act as Project Scientists for their risks. The LSs responsibilities are: 
• Provide horizontal integration across portfolios working with other LSs 
• Be responsible for definition and mitigation of assigned risk 
• Update research plan with closable gaps 
• Be knowledgeable about and advocate for current tasks (including the NSBRI) 
• Identify the necessary tasks for closing or reducing gaps 
• Lead for the associated Discipline Integrated Product Team 
• Develop metrics for tracking gaps 
• Provide updates to the Evidence Book and the Risk Management Assessment Tool 
• Provide SRP presentations and responses to recommendations  
• Integrate accepted SRP recommendations into the IRP 
• Prepare content for Program Reviews 
• Plan for the yearly HRP’s Investigators’ Working Group [IWG] meeting 
• Identify inter-risk gaps and tasks 
1.6.2.1.5 Portfolio Science Coordinators (PSCs) [Maroon boxes on Figure 1-2] 
The Portfolio Science Coordinators (PSCs) provide project science support to the portfolios and 
the Element. They are responsible for understanding the details (content, schedule and risks) of 
their assigned portfolios. They are also responsible for working with PSCs from other portfolios 
to identify areas of intra-Element integration. The PSCs responsibilities are the following: 
• Provide project science support for risks in assigned portfolio 
• Provide gap rewriting support to LSs 
• Track gap metrics  
• Screen new task synopses  
• Coordinate SRPs and track actions 
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• Assist in evidence documentation (including end of task final reports and gap closure 
recommendations) 
• Update the IRP with content from LSs 
• Interface with ISSMP and FAP for experiment integration (e.g., select for flight/bed rest 
packages) 
• Plan interim science reviews 
• Complete project level resources and relevancy statements for directed tasks 
• Act as liaison to Element Science Management 
• PSCs report to the deputy ES 
The HHC partners with several internal organizations (e.g., HRP Elements and multiple NASA 
Centers) for countermeasure and technology development to maximize subject participation 
and minimize duplication of effort. These partnerships are described in the following 
paragraphs.  
1.6.3 Collaborations 
1.6.3.1 Other Elements 
Within the HRP, other Elements may partner with the HHC to collect evidence and develop 
countermeasures for exploration mission scenarios.  
1.6.3.2 NASA Centers 
The JSC will have technical lead for the coordination of all human-based studies within the 
Element. Support for subordinate project technical studies is provided by other NASA Centers 
as needed for implementation of ground and flight studies (pre and postflight operations). 
Specific NASA Center contributions are documented in Inter-Agency Task Agreements (ITAs). 
1.6.3.3 Discipline Integrated Product Teams (DIPTs) 
A DIPT exists for each discipline associated with the HHC research (i.e., each green box on 
Figure 1-2). These teams are established as internal groups to provide guidance to the Element 
on research priorities. Per appointment by the HRP Chief Scientist and concurrence of the HRP 
Program Manager, each team is led by the HHC LS and is assigned a flight surgeon and the 
corresponding NSBRI team leader, if a corresponding NSBRI team exists. These three individuals 
constitute the points of contact for the team. Additional composition of each DIPT is at the 
discretion of the LS and is expected to include both intramural and extramural discipline 
experts. To prevent real or perceived conflicts of interest, members of the DIPTs may not serve 
on the HHC SRP. The DIPTs provide recommendations to the Element to aid in the development 
of the PPBE packages, solicitations, and research plans. 
1.6.3.4 National Space Biomedical Research Institute (NSBRI) 
The NSBRI research is organized into the following teams that map to the needs of the HHC: 
Cardiovascular Alterations, Smart Medical Systems, Musculoskeletal Alterations, and 
Sensorimotor Adaptation. Interactions between the NSBRI team leaders and the HHC ESs 
facilitate the exchange of scientific information and foster collaborations to avoid duplication of 
efforts and optimize the fiscal resources of both parties. The NSBRI personnel will be members 
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of the DIPTs. Other points-of-contact and interfaces are established between the two entities as 
required. 
To properly focus the areas of research activity, NASA and the NSBRI discuss programmatic 
needs before announcing forward research solicitations.  
1.6.3.5 International Partners (IPs) 
The HHC will collaborate with the International Partners (IPs) in both ground and flight 
investigations to maximize subject participation, share limited resources, share data when 
possible, and minimize duplication of effort.  
1.6.4 Standing Review Panels (SRPs) 
The HRP Science Management Office (SMO) is responsible for establishing and coordinating 
program-level working groups, advisory committees and SRP. Each panel will typically be 
comprised of approximately five to ten individuals with the appropriate scientific and technical 
expertise to evaluate the primary discipline area. The HHC SRP candidate participants are 
recommended to the HRP SMO by the HHC Element management team. The panel will evaluate 
the appropriateness and feasibility of the proposed research for the stated goals, and serve as a 
steering committee to evaluate progress of the Element to help optimize the research effort. 
The HHC participates in meetings when content being reviewed is that implemented by the 
HHC. 
1.6.5 Element Reporting 
The HHC EM reports Element performance for the preceding quarter to the HRP Program 
Manager at the HRP Quarterly Reviews and reports the status of any controlled milestones 
upon projected completion date. Research results will be documented in peer-reviewed 
publications as well as appropriate scientific meetings. Recommendations to the HRP will be 
documented in the NASA publication system. The HHC EM also reports monthly to the HRP 
Program Manager resource and budget status. Annually, the EM reports on PPBE and on the 
IRP to the HRP. Every other year, evidence reports are updated as needed based on current 
findings. Recommendations for countermeasures and standards are also reported to the 
Human Systems Risk Board (HSRB). 
Reporting to the HEOMD is through the HRP in accordance with the HRP Program Plan. The 
HHC coordinates inputs from the HHC Portfolios and will provide those inputs for the HRP 
Annual Report.  
1.7 Governance Structure 
This Element is classified as an Agency Research and Technology Portfolio Project as defined in 
NPR 7120.8, NASA Research and Technology Program and Project Management Requirements 
(b) in Section 2.2.1.1. The governing Center organization that provides oversight for this 
Element is the JSC HRP Office. 
1.8 Element Requirements 
Element requirements are allocated from the HRP as documented in the HRP PRD. Element 
requirements involve development and validation of medical standards (PRD Section 4.1), 
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quantification of physiologic risks (Section 5.1), mitigation of physiologic risks (PRD Section 5.2), 
treatment and monitoring of unmitigated physiologic risks (PRD Section 5.3), compliance with 
Agency policy and procedure (PRD Section 6.3) and reduction of required resources (PRD 
Section 6.4). The physiologic risks allocated by HRP to its Elements are listed in HRP PRD Section 
5 in Table 3 – Exploration Missions Human Health and Performance Risks, Evidence Verification, 
and Mission Criticality.  
The HHC is allocated 15 of the HRP risks identified in the PRD. The gaps decomposed from each 
of these risks serves as the requirements for this Element. These requirements are documented 
in Appendix D. The EVA risks (DCS, EVA Health, and EVA Performance) are currently being 
defined and baselined by the HSRB. Currently, Oxidative Damage is not a risk as defined by the 
HSRB, but HHC plans to present it as a risk to the HSRB in FY12.  
1.9 Technical Summary 
Spaceflight-induced changes affect in-flight health and performance, as well as long-term 
health. To understand the extent of the health and performance decrements, the HHC must 
understand the risks and then develop countermeasures to the highest risks from spaceflight. 
The HHC is responsible for coordinating research activities across its portfolios and assigned 
risks. These research activities aim to understand human health and performance issues and 
determine if these can or should be mitigated. The HHC provides the biomedical expertise for 
the development and assessment of medical standards; provides vehicle and spacesuit 
requirements as dictated by human physiologic needs; and will develop a validated and 
integrated suite of countermeasures for exploration missions that ensure the maintenance of 
crew health during all phases of the mission, including following return to Earth. 
Countermeasures target human physiology and performance capabilities at risk from 
spaceflight missions at each stage of mission performance. Preflight countermeasures involve 
crew selection, physical fitness and exercise prescription, physiologic adaptation training, and 
health stabilization. In-flight countermeasures cover physiologic and nutritional health, physical 
fitness, and mission performance. Postflight countermeasures target rehabilitation strategies. 
The major deliverables for the HHC are input for the refinement of health and medical 
standards, validated human health prescriptions, validated exercise system requirements, 
extravehicular activity (EVA) suit and decompression requirements, integrated physiologic 
countermeasures, partial gravity human performance predictions and requirements, and 
criteria for the agency fitness for duty and crew selection/retention standards.  
1.10 Implementation Approach 
The HHC is assigned risks from the HRP PRD. From these risks, the HHC assigns gaps to the four 
HHC research portfolios. Some risks and gaps cross multiple portfolios and/or DIPTs, these are 
assigned by the Element to a primary portfolio. The Element holds interportfolio meetings to 
ensure integration of all activities within the Element.  
The success criteria include the delivery of operational requirements for each exploration 
mission as well as validated and optimized countermeasures that allow crew to meet criteria 
established in the NASA Spaceflight Human System Standard Volume 1: Crew Health document 
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(NASA-STD-3001). The process to establish these deliverables is iterative. As validation tests are 
completed and vehicle and habitat designs mature, deliverables will be refined as appropriate.  
The HRP performed an analysis to determine program risks with supporting gaps in the 
knowledge base. The HHC coordinates with its subordinate portfolios to establish 
recommended areas of research and implement research awards using research calls. These 
awards have defined schedules and deliverables. Research activities focus on ground-based 
problem definition and countermeasure development, countermeasure testing in microgravity 
analogs, and validation in spaceflight studies.  
The first step in implementation is a detailed understanding of Program-identified risks set 
forth in the PRD, standards and research requirements, and existing capabilities and 
operational requirements to determine performance and knowledge gaps. Research will be 
solicited or directed to fill these gaps. The FAP ground capabilities/facilities will be used to test 
the validity of the proposed countermeasure. Validation of countermeasures with human 
subjects in actual spaceflight requires the involvement of ISSMP personnel to schedule and 
integrate on-orbit testing using ISS and/or exploration-class missions where appropriate. 
Results may dictate fundamental changes in protocol, abandonment of the concept and 
cancellation of further work, or progression to the next phase. Upon validation of the proposed 
countermeasure, the countermeasure will be delivered to the appropriate customer for 
operational implementation.  
1.11 Element Dependencies  
Successful implementation of the HHC depends on: 
• Continued JSC SMD involvement for certification and configuration management of 
medical standards and requirements for assuring astronaut health and safety 
• Intra- and extramural discipline experts to act in the capacity of an advisory council for 
program Element reviews, shared expertise and general consulting 
• Astronaut Office support for insight, participation and feedback on Element goals, 
technology selection reviews, countermeasure validation, as well as analog and flight 
testing 
• HRP support in assembling effective, rapid Non-Advocate Review (NAR) panels for 
review of directed research relative to candidate scientific proposals 
• HRP facilitation of calls for HHC proposal solicitations via the NRA 
• Partnering with other HRP Elements for effective use of resources, data-sharing, and 
facilities 
• ISS, or other vehicle programs, to assign a high priority to selected modalities in support 
of flight validation studies by making available manifest opportunities and in-flight 
resources (time, stowage, etc.) 
• Partnering with the NSBRI for effective use of resources and facilities 
• Effective use of data mining techniques to use previously collected data archived in JSC 
flight and ground databases 
• A pool of highly qualified principal investigators to help address the HHC gaps 
• SMD for support in risk definition/clarification and advocacy. The SMD also provides a 
test subject facility and Lifetime Surveillance of Astronaut Health (LSAH) infrastructure 
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1.11.1 Agreements 
Several cooperative, Inter-Agency, Intra-Agency, and International Agreements are established 
to support the HHC. The agreements listed in Table 1-1 form an integral part of this Element 
Plan.  
Table 1-1: Agreements 
Nature of entity Entity Description 
Within JSC Bioastronautics Contract (NAS 9-
02078)  
Personnel, expertise, facilities 
Universities Space Research 
Association (USRA) Contract 
(NNJ11HE31A) 
U.S. Non-Government 
Entities 
NSBRI Research facilitation, award, 
and management 
(cooperative agreement) 
Extramural researchers Via research award  
U.S. Government 
Entities 
National Institutes of Health Access to bed rest capabilities 
within their specialized clinical 
research facilities 
International Entities International Partners Participates in flight/ground 
studies 
Customers Space Medicine Division, Office of 
the Chief Health and Medical 
Officer, Multi-purpose Crew 
Vehicle, Commercial Crew Program, 
Other exploration development 
projects (e.g., Advanced Exploration 
Systems) 
Customer Supplier 
Agreements will be signed 
between the Element and the 
customers for 
countermeasures, standards 
and all other HHC deliverables 
1.12 Logistics 
All HHC logistical needs are anticipated to be identified and met by individual PIs. The PSCs and 
Portfolio Managers will aid the PIs when necessary.  
Non-PI related logistics are handled by the Bioastronautics Contract on a case-by-case basis. 
PART II: ELEMENT BASELINE 
2.0 Schedules 
The HHC milestones and deliverables support Agency exploration timelines. The HRP maintains 
an IMS of all Element visibility and control milestones that is approved through the HRPCB. 
Figure 2-1 illustrates the HHC schedule of key milestones and deliverables as agreed to by HRP 
and documented in the IMS. Key tasks, decision points, and strategies in meeting these 
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milestones are documented in the IRP. Any changes in Element content or strategy that affect 
controlled milestones require approval by the HRPCB. 
The HHC key target milestones are indicated in Table 2-1. 
Table 2-1. Excerpt of HHC Schedule Showing Key Controlled Milestones 
HHC Key Controlled MILESTONES FINISH DATE 
Preliminary recommendation for use of bisphosphonates to reduce 
bone loss 
January 2012 
Baseline rVIIP Research Plan August 2012 
Preliminary recommendation for update to Immune Standard based 
on outcome from Integrated Immune flight study 
July 2013 
2.1 Resources 
The resources necessary to successfully complete the tasks and objectives are defined in this 
Plan over the specified time period per the PPBE process. 
2.1.1 Funding Requirements 
Funding requirements will be reviewed on an annual basis through the PPBE process. Element 
content and scope will be reviewed on an annual basis reflecting actual funding allocations. In 
addition to the identified funding requirements, the HHC requires application of the NSBRI 
resources to address the HHC gaps. NSBRI application of resources is negotiated with the HRP 
Program Office and NSBRI management. The most recently approved HHC procurement budget 
(including civil service travel) and number of HHC civil servant full-time equivalents (FTEs) for 
fiscal years (FYs) 12–17 is provided in Table 2-2 below: 
Table 2-2: Funding Requirements for HHC 
HHC SUMMARY FY12 FY13 FY14 FY15 FY16 FY17 
HHC Procurements $M 31.561 31.507 31.529 31.551 31.573 31.597 
HHC FTE 29.8 29.8 29.8 29.8 29.8 29.8 
2.1.2 Institutional Requirements 
Inter-Center and institutional facilities required to support the HHC are identified in Table 2-3. 
Table 2-3: Inter-Center and Institutional Facilities 
Organization Facilities 
Johnson Space Center Human Adaptation & Countermeasures Laboratories 
Space Medicine Division 
Habitability & Environmental Factors Laboratories 
Glenn Research Center Engineering Facilities 
Human Research Program Facilities 
• Exercise Countermeasures Laboratory 
• Space Experiments Laboratory 
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Organization Facilities 
Ames Research Center Space Biosciences Research Laboratories 
Human Performance Centrifuge 
Landing Sites Gagarin Cosmonaut Training Center 
Baikonur 
Astronaut Rehabilitation Center 
Baseline Data Collection Facility 
Ground Analog Facilities General Clinical Research Centers (e.g., UTMB) 
Haughton Mars 
Devon Island 
NASA Extreme Environment Mission Operations (NEEMO) 
Antarctic research centers 
2.2 Acquisition Management 
The HHC makes use of available NASA and HEOMD acquisition methods, such as NRAs, 
Requests for Proposals, and Internal Calls for Proposals, to solicit R&T development tasks. Small 
Business Innovation Research grants (SBIRs) are used to the largest extent possible. 
Participating Centers also use competitive contracts for procurement of support to intramural 
Element tasks. The JSC uses the Bioastronautics Contract that is an Indefinite Deliverables 
Indefinite Quantity (IDIQ), task-based contract used for laboratory mission operations support 
and is currently in place. Technical expertise is also contracted at JSC via the Universities Space 
Research Association (USRA) for personnel to support the HHC research activities. 
A new contract will replace the Bioastronautics Contract in the March 2013 timeframe. 
Solicitation, selection, and management of ground and flight science and research tasks under 
this Element follow the processes defined in the HRP Science Management Plan (HRP-47053) 
(SMP). 
2.3 Performance 
Element performance will be based upon: 
• Crew health physiologic parameters improvement 
• Compliance to Permissible Exposure or Outcome Limits and Fitness for Duty Standards 
• Annual review by the HRP and Element SRPs to examine: 
o Definition and clarity of requirements identified 
o Implementation plan and review process 
o Maturity of deliverables 
o Validation and operational availability of deliverables for implementation 
o Transition of end-item Element deliverables to customer programs 
o Mitigation of risks, retirement of risks/gaps, and possible generation of new 
risks/gaps 
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PART III: SUBPLANS 
3.0 Communications Plan 
Element management and technical issues are communicated informally during daily tag-ups 
within the Element management team. More formal communications are conducted between 
the Element and Program Management staff through weekly Program/Element tag-ups, the 
quarterly TCSR, and annual progress reports. Element team issues are communicated through 
bi-weekly Element meetings. Communication with external principal investigators will occur 
formally at the annual HRP Investigators’ Workshop and informally through phone and email 
contact as needed. Communication with the NSBRI is through regular discussions between the 
ES and/or Project Scientists, and NSBRI Team Leads. Formal communication with the NSBRI is 
through the Program Scientist who is the Contracting Officer’s Technical Representative for the 
NSBRI Cooperative Agreement. Element progress and status is reported to line organization 
management as appropriate to ensure proper and adequate resourcing and skilled personnel 
supply. 
3.1 Control Plan 
The Element has full authority and responsibility to implement an Element control plan for all 
requirements, resource allocation, and schedule milestones delegated to it from the HRP. 
Changes to the Element objectives and requirements, allocated resources, or Level 1 
(controlled) schedule milestones and deliverables as detailed in this Plan require negotiation 
with and approval by the HRP.  
The EM has the authority to redistribute funding among work breakdown structure (WBS) areas 
within the thresholds established by the HRP with the exception of redistribution of funds 
across Centers. Any changes concerning the participation of NASA field Centers must be 
presented to the HRP for approval. Use and management of Element reserves within the 
Element baseline budget are at the discretion of the HHC Manager and do not require prior 
approval from the HRP management.  
The HHC will use the established JSC HRP board structure to control Level 1 milestones and 
budget. Level 1 (controlled) milestone acceptance is approved by the HRP CB. Element-level 
deliverables and high-level visibility milestones will be controlled by the HHC CB, as will the DA 
project plan.  
The HRP management has authority to review this Element and provide assessment, direction, 
continuation, or termination, as appropriate. Products and changes for this Element will be 
processed through the appropriate HRP CB as determined by the SLSD Configuration Control 
Management Plan (JSC 28330, Rev. E).  
3.1.1 Configuration Control Boards  
The HHC relies on the HHC CB as well as the HRPCB to ensure the configuration management of 
the Element.  
The HHC CB maintains configuration control and quality management oversight for activities of 
the HHC, as needed. The HHC CB holds configuration control maintenance of the HHC-owned 
gaps and the DAP Plan. Detailed responsibilities and duties are defined in the HHC CB charter. 
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For HHC-owned gaps, ad hoc members can be added to the HHC CB for decisions related to 
closure of the gaps. Once the gap has been closed, all downstream documentation will be 
updated to reflect this change. This includes the Element Plan and the IRP. The ISSMP CCB 
controls flight implementation aspects for the HHC-selected investigations. 
The HRPCB manages HEOMD resources allocated to the HRP by configuration control 
maintenance of Element Plans and the HRP Program Plan. Detailed responsibilities and duties 
are defined in the HRPCB charter. The HHC EM is a standing member of the HRPCB. 
The HRP requirements (Human Health and Performance Risks) are defined by the HSRB. Data 
from the HHC research will be used to close the gaps. This data will be brought to the HSRB for 
recommendation regarding the pertinent risk. The HSRB provides the final decision to mitigate, 
accept close or further research the risk. All downstream documentation will then be updated 
to reflect any risk disposition. 
3.2 Risk Management Plan 
The HHC will follow continuous risk management in accordance with the HRP Program Plan 
(Appendix E). The HHC Portfolios identify and provide their top priority risks to the HHC. The 
EM determines which of those risks are top priority for the Element and then forwards those 
top Element risks up to the Program. 
3.3 Technology Assessment 
3.3.1 Strategy 
The Element continually assesses the state of knowledge in human health and performance 
risks. The Element team is continuously communicating with the DIPTs who regularly provide 
new evidence. New scientific findings are presented at weekly science meetings. Newly 
developed knowledge can be used to address health protection goals by integrating research 
results into methodologies for risk mitigation strategies and guidance on new research 
directions. 
New technology that is identified and required for the Element shall undergo annual 
assessment before the solicitation review and selection process. New technology will be 
assessed for feasibility, readiness, cost, risk and benefit to the Element.  
3.3.2 Insertion 
The Element along with the HHC LSs integrates scientific research results, including ongoing 
assessments of progress in the eight science disciplines specified in Section 1.6.1. Transition of 
research results into requirements, standards, or recommendations for operational procedures 
will begin only after successful completion of planned ground assessments and analog 
validations. Recommended changes to human system requirements, standards, guidelines, and 
practices will be processed through the HRP. These updates will then flow to the HEOMD, as 
needed, for insertion into the requirements for flight vehicles, habitats, operations, mission 
planning and other systems.  
If HHC requires new technology to be developed to update standards or countermeasures, that 
technology will be developed within the Element. If this new technology is required by outside 
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entities; the technology recommendations will be submitted to HRP after the research results 
have been reviewed and approved, consistent with the Technology Transition process defined 
in the HRP Science Management Plan.  
3.4 Cooperation and Commercialization 
The JSC Technology Transfer and Commercialization Office (TTCO) will support the Element to 
identify and evaluate commercial opportunity options. As applicable, the JSC TTCO will support 
the Element to develop specific commercialization partnership and/or tech transfer 
opportunities. The JSC Small Business Innovation Research/Small Business Technology Transfer 
(SBIR/SBTTR) Program Office will support the Element to identify and evaluate commercial 
opportunity options. As applicable, the JSC SBIR/SBTTR will support the Element to develop 
specific commercialization partnerships and/or tech transfer opportunities. 
3.5 Safety and Mission Success Plan 
3.5.1 Human Test Subjects 
For projects involving human subjects, the Element will ensure all HHC investigators follow the 
JSC’s Committee for the Protection of Human Subjects guidelines found at http://irb.nasa.gov/ 
and SMP to ensure the health, safety and privacy of the subjects are protected. 
3.5.2 Animal Test Subjects 
For ground-based projects involving animal subjects, the element will ensure all HHC 
investigators obtain prior approval from the Institutional Animal Care and Use Committee 
(IACUC) for the appropriate testing location and will also comply with the NRC guide for the 
care and use of laboratory animals and the animal welfare act (9 CFR - Code of Federal 
Regulations - Title 9: Animals and Animal Products). 
3.5.3 Ground Research 
For ground-based research, the Element will comply with the approved Center and Facility 
safety and quality standards.  
3.5.4 Flight Research 
For flight research, the Element will comply with the applicable standards and procedures 
governing ISS flight payloads. Because all HHC-funded flight research flows through the ISSMP 
for flight integration, the Element will follow ISSMP safety and assurance plans. 
3.6 Environment Management Plan 
The Element complies with NPD 8500.1 – NASA’s Environmental Management Policy. The 
participating Centers and institutions are required to comply with their Center or institution 
policies and procedures related to environmental management.  
3.7 Systems Engineering Plan 
The Element does not have a designated system engineering organization, but system 
engineering functions are performed by the Element management team. 
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The HHC will ensure that the Element’s goals, objectives and requirements are integrated 
among the various HHC portfolios. Science portfolios are integrated among the HHC portfolios 
and discipline teams to ensure synergy while minimizing overlaps. Overall research oversight 
will be implemented via the ES in conjunction with the EM. Element implementation 
approaches, reporting, management, and infrastructure will be coordinated across portfolios to 
minimize overhead and costs. This coordination will be the responsibility of the Element 
management team, and delegated to the respective participating organizations. 
3.8 Verification and Validation 
Acceptance in peer-reviewed publications serves as the standard for validation of scientific 
results from the HHC-funded studies. Validation of operational conclusions from these scientific 
results will be shown by acceptance in NASA Technical Publications or successful insertion into 
mission requirements documentation. Countermeasures developed will be evaluated using the 
appropriate analog environment; then the countermeasure will be validated using flight 
resources. The verification and validation for the HHC deliverables are unique to each task. The 
verification and validation will also be driven by exploration mission requirements. The HHC 
shall subject hardware and software used in flight experiments and tests to functional 
verification and safety reviews as required by the vehicle program requirements. The HHC shall 
document these activities in Project Verification and Validation Plans as required by the 
appropriate ISS requirements.  
3.9 Reviews 
The HHC participates in reviews agreed to by the HRP. These reviews are identified in the 
Element schedule.  
3.9.1 Reviews within the HRP 
The Element participates in quarterly TCSRs with the HRP Office. The critical reporting 
requirements for the quarterly reviews include assessments of technical (scientific), cost and 
schedule at the Element level. The Element will conduct detailed reviews of its subordinate 
portfolios before each TCSR and before the yearly PPBE cycle. 
3.9.2 Peer Reviews 
There are three types of peer review that can occur for the HHC content: NRA reviews, merit 
reviews of directed studies, and standing reviews for the scientific content of the Element. 
These peer review panels are ad hoc review committees called upon to review solicited 
proposals, directed task research proposals, various existing projects, and approaches to 
specific technical issues. Panels usually will be chaired by an individual selected from a standing 
roster having the appropriate expertise for the primary discipline area requiring peer review. 
Details for the merit reviews and NRA review processes can be found in the HRP Unique 
Processes, Criteria, and Guidelines (HRP-47069). Details of the standing reviews of the Element 
can be found in the HRP SMP. The HRP SMO has the responsibility to ensure the panelists do 
not have conflicts of interest.  
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3.10 Configuration Management Plan 
Configuration management of this document and all Level 1 milestones will be in accordance 
with the SLSD Configuration Management Plan. Configuration of Level 1 milestones will be 
controlled through the HRPCB. Configuration of this document will be controlled through the 
HRPCB. Configuration control of all lower level Element documents, schedules and products will 
be delegated to the portfolios as deemed appropriate by the HHC CB.  
3.11 Education and Public Outreach Plan 
Education and public outreach is coordinated and conducted by the HRP Education and 
Outreach Office. Efforts may include activities such as maintaining an Element website, 
participating in HRP and HACD outreach, supporting scientific meetings, and providing input to 
formal K-12 education initiatives. The HHC supports these activities as needed. 
3.12 Termination Review Criteria 
As specified in the HRP Program Plan, the HRP will review the status of each Element at least 
annually and assess the ability of the Element or portfolio to meet its objectives. The HRP 
Elements and portfolios are subject to termination as authorized by the HRP Program Manager 
in consultation with HEOMD. Criteria for termination may include: 
• Strategic: Inconsistent with the Exploration vision; inconsistent with the 
program/mission objectives; overlap with another funded activity; or low priority 
ranking for HRP or Element given funding constraints  
• Technical and Scientific: Performance measures indicate that the technology will not 
achieve the required technical results by the scheduled need date; performance 
measures indicate degradation in projected performance versus performance 
commitments; product delivered is of insufficient quality and/or does not meet 
performance requirements  
• Cost: Over budget by 5% per year for a Element; over budget by 15% per year for a 
portfolio  
• Schedule: Missed milestone(s) or key decision points; missed due dates for major 
activities, projected delay in the operational readiness review greater than 6 months 
from the committed date  
• Noncompliance with Agency or HEOMD policy  
• Knowledge sought is obtained through means other than the current HRP-funded 
activities 
3.13 Knowledge Capture Plan 
The data and documents developed under this Element will be catalogued and available 
through controlled access to the HRP websites in accordance with standard JSC, SLSD and HRP 
Information Technology procedures. These documents may include published journal articles, 
conference papers, and/or technical presentations generated by extramural and/or intramural 
researchers, data entry into the Life Sciences Data Archive (LSDA), NASA publication series, and 
Project summary documentation. In addition, evidence books for each HHC-managed HRP risks 
will contain an updated evidence base for each risk and can be accessed at 
http://humanresearchroadmap.nasa.gov/evidence/. Details for research activities funded 
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through the HHC can be found on the HRP Task Book website: 
http://peer1.nasaprs.com/Publication/welcome.cfm. 
3.14 Waivers/Deviations Log 
There are no known deviations or waivers against NASA or the HRP policies, directives or 
external requirements, either in existence within the HHC or to be obtained by the Element. 
3.16 Appendices  
Appendix A – Acronyms 
Appendix B – Applicable and Reference Documents 
Appendix C – Element Research Plan 
Appendix D – Requirements (Risks and Gaps) 
  
HRP-47078 
 22 
APPENDIX A: ACRONYMS AND ABBREVIATIONS 
BMD Bone Mineral Density 
CB Control Board 
CCB Configuration Control Board 
CHMO Chief Health and Medical Officer 
CPHS Committee for the Protection of Human Subjects 
CSA 
DAP 
Customer Supplier Agreement 
Digital Astronaut Project 
DRM Design Reference Mission 
DIPT Discipline Integrated Product Team 
ECP Exercise Countermeasures Project 
EM Element Manager 
ES Element Scientist 
EVA Extravehicular Activity 
FAP Flight Analogs Project 
FTE Full-Time Equivalent 
HACD Human Adaptation & Countermeasures Division  
HACD CCB HACD Configuration Control Board 
HEOMD Human Exploration and Operations Mission Directorate 
HHC Human Health Countermeasures 
HHC CB Human Health Countermeasures Control Board 
HMTA Health & Medical Technical Authority 
HRP Human Research Program  
HRPCB 
HRR 
HRP Control Board  
Human Research Roadmap 
HSRB Human System Risk Board 
IDIQ Indefinite Deliverables Indefinite Quantity 
IP International Partner 
IRB Institutional Review Board 
ISS International Space Station 
ISSMP ISS Medical Project 
ITA Inter-Center Technology Agreement 
JSC Johnson Space Center 
LS Lead Scientist 
LSAH Lifetime Surveillance of Astronaut Health 
LSDA Life Sciences Data Archive 
NAR Non-Advocate Review 
NASA National Aeronautics & Space Administration 
NEEMO NASA Extreme Environment Mission Operations 
NRA NASA Research Announcement 
NRC National Research Council 
NSBRI National Space Biomedical Research Institute 
NxPCM Non-Exercise Physiologic Countermeasures Project 
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OCHMO Office of Chief Health and Medical Officer 
PPBE Program Planning & Budget Execution 
PRD Program Requirements Document 
PSC Portfolio Science Coordinator 
R&T Research & Technology 
RFP Request for Proposal 
SBIR Small Business Innovation Research 
SBTTR Small Business Technology Transfer 
SLSD Space Life Sciences Directorate 
SMD Space Medicine Division 
SMO Science Management Office 
SOMD Space Operations Mission Directorate 
SRP Standing Review Panel 
STD Standard 
TBD To Be Determined 
TCSR Technical Cost and Schedule Review 
TTCO Technology Transfer & Commercialization Office 
USRA Universities Space Research Association 
UTMB University of Texas Medical Branch 
WBS Work Breakdown Structure 
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APPENDIX B: APPLICABLE AND REFERENCE DOCUMENTS 
APPLICABLE DOCUMENTS  
Document No. 
SA-WI-001 
Title 
SLSD Master Work Instruction 
SA-WI-002 SLSD Human Space Life Sciences Programs Office Work Instruction 
SK-WI-001, Rev B HACD Master Work Instruction 
JPD 7120.1 JSC Project Management Policy 
Revision C (25 Apr 2011) Human Research Program Control Board Charter 
Baseline (26 Apr 2006) Human Research Program Science Management Panel Charter 
Memo – SK-01-173 Small Assessment Team report 
LS-73004 International Space Station Medical Project (ISSMP) Launch and 
Experiment Manifest 
LS-73005 International Space Station Medical Project (ISSMP) Flight Queue 
Master List 
LS-71030 International Space Station Medical Project (ISSMP) Quality 
Assurance Plan Document 
SSP 50260B ISS Medical Operations Requirements Document 
JSC29834 Vol. 1B, Rev. C Astronaut Medical Evaluations and Requirements Document 
HRP-47051 HRP Program Plan 
HRP-47052  HRP Program Requirements Document 
HRP-47053  HRP Science Management Plan 
HRP-47065 Human Research Program Integrated Research Plan 
HRP-47069  HRP Unique Processes, Criteria, and Guidelines 
NASA-STD-7709 Standard for Models and Simulations 
 
REFERENCE DOCUMENTS 
Document No. 
http://irb.nasa.gov/ 
Title 
JSC CPHS: Guidelines for Investigators Proposing Human Research 
for Spaceflight and Related Investigations 
JSC 28330C Space Life Sciences Directorate Configuration Control 
Management Plan 
NASA STD-3001, Vol. 1 NASA Space Flight Human System Standard 
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Document No. 
NPR 7120.8 
Title 
NASA Research and Technology Program and Project Management 
Requirements  
NPD 8500.1 NASA Environmental Management Policy 
 NRC Guide for the Care & Use of Laboratory Animals and the 
Animal Welfare Act (Code Fed. Reg. Title 9) 
TBD Digital Astronaut Project (DAP) Plan 
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APPENDIX C: HUMAN HEALTH COUNTERMEASURES ELEMENT RESEARCH PLAN 
The HHC Element Research Plan is fully embedded within the HRP IRP (HRP-47065) and not a 
stand-alone document. The IRP can be viewed electronically as part of the web-based HRP Human 
Research Roadmap (HRR) at http://humanresearchroadmap.nasa.gov/. The HHC inputs to the IRP 
will be incorporated as required and will be updated yearly and follows the cycle outlined in the 
HRP SMP (HRP-47053).  
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APPENDIX D: HUMAN HEALTH COUNTERMEASURES REQUIREMENTS (RISKS AND GAPS) 
 
Risk Title Gap Title 
Risk of Microgravity-Induced 
Visual Impairment/Intracranial 
Pressure 
VIIP1: What is the etiology of visual acuity and ocular 
structural and functional changes seen in-flight and 
postflight? 
  VIIP2: Does exposure to spaceflight cause changes in 
visual acuity, intraocular pressure and/or intracranial 
pressure? Are the effects related to mission duration? 
  VIIP4: Are changes in visual acuity related to changes in 
chronic choroidal engorgement, elevated intraocular 
pressure, and/or intracranial pressure? 
  VIIP5: Do multiple or cumulative exposures to spaceflight 
increase the risk of changes in visual acuity, intraocular 
pressure, or intracranial pressure? 
  VIIP8: What is the role of the ISS environment (eg, high 
salt diet, CO2
  
 pockets, pharmaceutical use, exercise 
countermeasures) on ocular structure and function and 
intracranial pressure? 
VIIP3: What in-flight diagnostic tools are needed to 
measure changes in intraocular pressure and intracranial 
pressure? 
Risk of Intervertebral Disk 
Damage 
B4: What is the incidence of intervertebral disk damage 
following spaceflight? 
Risk of Cardiac Rhythm Problems N7: What are the potassium, magnesium, and 
phosphorus changes in relation to cardiovascular issues 
and bone loss? 
  CV1: What are the in-flight alterations in cardiac 
structure and function? 
  CV8: Can manifestations of subclinical or environmentally 
induced cardiovascular diseases during spaceflight be 
predicted? 
  CV7: How are fluids redistributed in flight? 
Risk of Renal Stone Formation B5: What is the current state of knowledge regarding 
renal stone formation? 
  B6: What are the contributing factors other than loss of 
bone mineral density? 
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Risk Title Gap Title 
  B7: Is it necessary to increase crew fluid intake and, if 
possible, to what extent will it mitigate stone formation? 
  B8: Do pharmaceuticals work effectively in spaceflight to 
prevent renal stones? 
  B9: What is the frequency of postflight stone formation; 
the incidence and types of stones; and the time course of 
stone formation? How does stone formation correlate 
with food intake and hydration status? 
  B16: Can inhibitors of stone formation be sufficiently 
provided through dietary sources? 
  N13: Can renal stone risk be decreased using nutritional 
countermeasures? 
  N14: What integrated nutritional, exercise and/or 
pharmaceutical countermeasures can be used to mitigate 
bone loss? 
Risk of Therapeutic Failure Due 
to Ineffectiveness of Medication 
PH01: Inadequate tracking of medication use, indication, 
efficacy, and side effects. 
  PH02: What drug interactions may adversely affect 
clinical care? 
  PH04: What diagnostic, therapeutic, and laboratory 
technologies are necessary to predict and manage 
medication side effects, interactions, and toxicity during 
spaceflight? 
  PH06: Can a standard procedure for prospective analyses 
of drugs to be considered for flight and periodic analyses 
of drugs that are used for flight be developed? 
  PH07: What are the effects of spaceflight on 
pharmacokinetics and pharmacodynamics? 
  PH09: What is the stability of drugs during long-duration 
spaceflight? 
  PH10: What are the effects of in-flight drugs on exercise, 
orthostatic tolerance, motor control, cognitive function, 
or other performance-determining aspects of 
physiology? Can novel multidisciplinary therapeutic 
approaches be used to enhance efficacy and reduce side 
effects? 
  PH13: Which sleep aid is best in flight in terms of 
efficacy? In terms of limited side effects? 
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  PH15: Are the antimicrobials carried on board effective 
against microbes that exhibit spaceflight-related 
changes? 
  M14: What anabolic or anticatabolic drugs can be used 
to mitigate muscle loss? 
Risk of Compromised EVA 
Performance and Crew Health 
Due to Inadequate EVA Suit 
Systems 
EVA 6: What physiologic and amp; performance 
capabilities are required for suited operations? 
  EVA 7: How do EVA suit design parameters* affect crew 
health and performance in exploration gravity 
environments and how can their effects be predicted? 
  EVA 8: What are the metabolic costs of expected nominal 
and amp; contingency suited tasks in exploration gravity 
environments and how can heat produced during 
exploration EVA effectively be removed? 
  EVA 9: How do EVA duty day work-rest cycles (eg, long, 
single vs. short, multiple EVAs/day) impact crew 
performance and amp; health? 
  EVA 10: How can biosensors be integrated with advanced 
tools, biofeedback and amp; information systems to 
improve EVA crew performance and autonomy? 
  EVA 11: How do suit fit and suit-human biomechanical 
interactions affect the likelihood of crew injury? 
  EVA 12: What is the risk of decompression sickness (DCS) 
in micro- and partial-gravity environments? 
  EVA 13: What is the risk of hypoxia during exploration 
missions? 
Risk of Crew Adverse Health 
Event Due to Altered Immune 
Response 
B31: Need additional information regarding hard and soft 
tissue healing in-flight. If impaired healing exists, what 
countermeasures can enhance healing? 
  IM1: Does spaceflight alter immune function? 
  IM2: Is an improved immune standard needed? 
  IM3: Are there suitable analogs for immune 
dysregulation? 
  IM4: Can in-flight hardware to evaluate 
hematology/infection/immunity be developed? 
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  IM5: What is the time course and etiology of immune 
changes? 
  IM6: What are the cumulative effects of chronic immune 
dysfunction on missions greater than 6 months? 
  IM7: What is the correlation of observed laboratory 
immune changes during spaceflight with known clinical 
conditions? 
  IM8: What is the correlation of immune risks with other 
risks, particularly psychological stress, physical 
deconditioning, nutrition, and/or radiation? 
  PH15: Are the antimicrobials carried on board effective 
against microbes that exhibit spaceflight-related 
changes? 
Risk of Orthostatic Intolerance 
During Re-Exposure to Gravity 
PH10: What are the effects of in-flight drugs on exercise, 
orthostatic tolerance, motor control, cognitive function, 
or other performance-determining aspects of 
physiology? Can novel multidisciplinary therapeutic 
approaches be used to enhance efficacy and reduce side 
effects? 
  CV3: Is orthostatic intolerance a potential hazard? 
  CV4: Is 1/6-g exposure protective of 1-g orthostatic 
tolerance? 
Risk of Impaired Control of 
Spacecraft, Associated Systems 
and Immediate Vehicle Egress 
Due to Vestibular/Sensorimotor 
Alterations Associated with 
Spaceflight 
SM1: What is the relationship between in-flight exercise 
and postflight sensorimotor performance? 
  SM2: What are the effects of long-duration spaceflight 
on sensorimotor function over a crewmember’s lifetime? 
What are the changes in sensorimotor function over the 
course of a mission? 
  SM4: What is the correlation between previous 
performance data with clinical observations? 
  SM6: Can a seated manual/visual performance 
assessment after long-duration spaceflight be 
completed? 
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  SM7: Can an integrated postflight functional task 
performance test be used on returning ISS crew 
members to obtain performance decrements? 
  SM12: Develop standards for spaceflight cockpit displays 
and inputs. 
  SM24: Can individual capacity to produce adaptive 
change in sensorimotor function to transitions in 
gravitational environments be predicted with preflight 
tests of sensorimotor adaptability? 
 SM26: Does exposure to long-duration spaceflight lead to 
neural structural alterations and does this remodeling 
impact cognitive and functional performance? 
 PH10: What are the effects of in-flight drugs on exercise, 
orthostatic tolerance, motor control, cognitive function, 
or other performance-determining aspects of 
physiology? Can novel multidisciplinary therapeutic 
approaches be used to enhance efficacy and reduce side 
effects? 
Risk of Injury from Dynamic 
Loads 
OP1: How do we protect the crew from injury during 
dynamic phases of flight? 
Risk of Reduced Physical 
Performance Capabilities Due to 
Reduced Aerobic Capacity 
CV2: What is VO2
  
max in-flight and immediately 
postflight? 
M7: Can the current in-flight performance be maintained 
with reduced exercise volume? 
  M8: What is the minimum exercise regimen needed to 
maintain fitness levels for tasks? 
  M9: What is the minimum set of exercise hardware 
needed to maintain those (M8) fitness levels? 
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Risk of Bone Fracture B1: (a) Is there an increased lifetime risk of fragility 
fractures/osteoporosis in astronauts; (b) is bone strength 
completely recovered post-flight and does BMD reflect it; 
and (c) what are the risk factors for poor recovery of 
BMD/bone strength? 
  B2: What new technologies are available for in-flight 
fracture diagnosis? 
  B3: What pharmaceuticals against bone loss are best 
used and how? 
  B10: How can skeletal adaptation be monitored during 
flight to (a) reflect changes in bone turnover/calcium 
kinetics, (b) determine whether there is a plateau in bone 
loss, and (c) evaluate gender effects? 
  B15: What exercise protocols are necessary to maintain 
skeletal health and can exercise hardware be designed to 
provide these? 
  B29: What is the risk of vertebral compression fractures? 
  B30: What are the loads applied to bone in-flight and 
during EVA activities and do they increase fracture risk in 
light of expected bone loss? 
  B31: Need additional information regarding hard and soft 
tissue healing in flight. If impaired healing exists, what 
countermeasures can enhance healing? 
  N5: Can a single test monitor net bone calcium changes? 
  N7: What are the potassium, magnesium, and 
phosphorus changes in relation to cardiovascular issues 
and bone loss? 
  N14: What integrated nutritional, exercise and/or 
pharmaceutical countermeasures can be used to mitigate 
bone loss? 
Risk of Impaired Performance 
Due to Reduced Muscle Mass, 
Strength and Endurance 
M1: What is the current state of knowledge regarding 
exercise performance? 
  M2: What is the current status of in-flight and postflight 
exercise performance capability? 
  M3: What tasks will be required for Exploration 
missions? 
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  M4: What are the physiologic costs of Exploration 
mission tasks? 
  M6: Can a standardized performance measure of 
readiness for Exploration mission tasks be developed? 
  M7: Can the current in-flight performance be maintained 
with reduced exercise volume? 
  M8: What is the minimum exercise regimen needed to 
maintain fitness levels for tasks? 
  M9: What is the minimum set of exercise hardware 
needed to maintain those (M8) fitness levels? 
  M14: What anabolic or anti-catabolic drugs can be used 
to mitigate muscle loss? 
  M23: Do factors in addition to unloading contribute to 
muscle atrophy during spaceflight (eg, radiation, 
inflammation, hydration, redox balance, energy 
balance)? 
  M24: What is the time course of changes in muscle 
protein turnover, muscle mass and function during long-
term spaceflight? 
  N9: What are the interactions of exercise and nutrition in 
altered weight bearing environments that mitigate 
muscle loss (Muscle)? 
  SM7: Can an integrated postflight functional task 
performance test be used on returning ISS crew 
members to obtain performance decrements? 
Risk Of Early Onset Osteoporosis 
Due To Spaceflight 
B1: (a) Is there an increased lifetime risk of fragility 
fractures/osteoporosis in astronauts; (b) is bone strength 
completely recovered postflight and does BMD reflect it; 
and (c) what are the risk factors for poor recovery of 
BMD/bone strength? 
  B3: What pharmaceuticals against bone loss are best 
used and how? 
  B10: How can skeletal adaptation be monitored during 
flight to (a) reflect changes in bone turnover/calcium 
kinetics, (b) determine whether there is a plateau in bone 
loss, and (c) evaluate gender effects? 
  B11: What are the effects of radiation on bone? 
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  B15: What exercise protocols are necessary to maintain 
skeletal health and can exercise hardware be designed to 
provide these? 
  B31: Need additional information regarding hard and soft 
tissue healing in flight. If impaired healing exists, what 
countermeasures can enhance healing? 
  MO5: Determine how can osteoporosis treatments be 
employed? 
  N5: Can a single test monitor net bone calcium changes? 
  N7: What are the potassium, magnesium, and 
phosphorus changes in relation to cardiovascular issues 
and bone loss? 
  N14: What integrated nutritional, exercise and/or 
pharmaceutical countermeasures can be used to mitigate 
bone loss? 
Risk Factor of Inadequate 
Nutrition 
N1: Are nutrients in food stable during spaceflight? 
  N2: What is the adequate dose range of vitamin D 
supplementation? 
  N3: How do nutritional status/nutrition requirements 
change during spaceflight? 
  N4: Do countermeasures impact nutrition? 
  N6: What impact does the spaceflight environment have 
on oxidative damage? 
  N9: What are the interactions of exercise and nutrition in 
altered weight bearing environments that mitigate 
muscle loss? 
  N14: What integrated nutritional, exercise and/or 
pharmaceutical countermeasures can be used to mitigate 
bone loss? 
  N15: Can nutrition/nutrients mitigate O2
  
/radiation risks? 
M23: Do factors in addition to unloading contribute to 
muscle atrophy during spaceflight (eg, radiation, 
inflammation, hydration, redox balance, energy 
balance)? 
 
